Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 10 studies | 24% ± 7% | |
epithelial cell | 7 studies | 31% ± 13% | |
fibroblast | 6 studies | 22% ± 7% | |
adipocyte | 6 studies | 19% ± 4% | |
astrocyte | 6 studies | 29% ± 9% | |
oligodendrocyte | 5 studies | 23% ± 5% | |
microglial cell | 4 studies | 21% ± 5% | |
ciliated cell | 4 studies | 21% ± 5% | |
abnormal cell | 4 studies | 22% ± 8% | |
type II pneumocyte | 4 studies | 21% ± 5% | |
GABAergic neuron | 4 studies | 41% ± 14% | |
glutamatergic neuron | 4 studies | 47% ± 16% | |
oligodendrocyte precursor cell | 4 studies | 26% ± 9% | |
macrophage | 4 studies | 22% ± 5% | |
lymphocyte | 3 studies | 19% ± 2% | |
dendritic cell | 3 studies | 23% ± 6% | |
endothelial cell of lymphatic vessel | 3 studies | 20% ± 4% | |
basal cell | 3 studies | 29% ± 11% | |
goblet cell | 3 studies | 31% ± 17% | |
transit amplifying cell | 3 studies | 27% ± 14% | |
interneuron | 3 studies | 40% ± 18% | |
neuron | 3 studies | 29% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 3209.86 | 21 / 21 | 100% | 36.25 | 504 / 504 |
breast | 100% | 3273.05 | 459 / 459 | 100% | 59.91 | 1118 / 1118 |
esophagus | 100% | 2983.82 | 1445 / 1445 | 100% | 48.84 | 183 / 183 |
lung | 100% | 2908.53 | 578 / 578 | 100% | 44.16 | 1155 / 1155 |
ovary | 100% | 3323.77 | 180 / 180 | 100% | 36.22 | 430 / 430 |
prostate | 100% | 3231.55 | 245 / 245 | 100% | 48.68 | 502 / 502 |
stomach | 100% | 2441.46 | 359 / 359 | 100% | 39.73 | 286 / 286 |
intestine | 100% | 3100.17 | 966 / 966 | 100% | 40.25 | 526 / 527 |
skin | 100% | 4940.44 | 1809 / 1809 | 100% | 42.62 | 471 / 472 |
brain | 100% | 2385.75 | 2634 / 2642 | 100% | 41.93 | 705 / 705 |
adrenal gland | 100% | 4161.16 | 258 / 258 | 100% | 39.58 | 229 / 230 |
uterus | 100% | 3229.84 | 170 / 170 | 100% | 42.87 | 457 / 459 |
thymus | 100% | 3426.21 | 653 / 653 | 100% | 37.87 | 602 / 605 |
liver | 100% | 2229.06 | 226 / 226 | 99% | 25.83 | 403 / 406 |
kidney | 100% | 1888.00 | 89 / 89 | 99% | 41.73 | 894 / 901 |
pancreas | 100% | 1960.28 | 328 / 328 | 99% | 38.70 | 176 / 178 |
adipose | 100% | 3234.81 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2524.34 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 30.90 | 29 / 29 |
spleen | 100% | 3122.86 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 49.05 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.89 | 1 / 1 |
muscle | 99% | 1491.33 | 798 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 1530.51 | 845 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 25.34 | 77 / 80 |
peripheral blood | 83% | 1821.46 | 768 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006986 | Biological process | response to unfolded protein |
GO_0030970 | Biological process | retrograde protein transport, ER to cytosol |
GO_0035617 | Biological process | stress granule disassembly |
GO_0034389 | Biological process | lipid droplet organization |
GO_0036503 | Biological process | ERAD pathway |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0035578 | Cellular component | azurophil granule lumen |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005576 | Cellular component | extracellular region |
GO_0005811 | Cellular component | lipid droplet |
GO_0034098 | Cellular component | VCP-NPL4-UFD1 AAA ATPase complex |
GO_0055102 | Molecular function | lipase inhibitor activity |
GO_0043130 | Molecular function | ubiquitin binding |
GO_0030674 | Molecular function | protein-macromolecule adaptor activity |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0005515 | Molecular function | protein binding |
GO_0035473 | Molecular function | lipase binding |
Gene name | FAF2 |
Protein name | Fas associated factor family member 2 FAS-associated factor 2 (UBX domain-containing protein 3B) (UBX domain-containing protein 8) |
Synonyms | UBXD8 KIAA0887 UBXN3B ETEA |
Description | FUNCTION: Plays an important role in endoplasmic reticulum-associated degradation (ERAD) that mediates ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins . By controlling the steady-state expression of the IGF1R receptor, indirectly regulates the insulin-like growth factor receptor signaling pathway . Involved in inhibition of lipid droplet degradation by binding to phospholipase PNPL2 and inhibiting its activity by promoting dissociation of PNPL2 from its endogenous activator, ABHD5 which inhibits the rate of triacylglycerol hydrolysis . Involved in stress granule disassembly: associates with ubiquitinated G3BP1 in response to heat shock, thereby promoting interaction between ubiquitinated G3BP1 and VCP, followed by G3BP1 extraction from stress granules and stress granule disassembly . . |
Accessions | Q96CS3 ENST00000261942.7 ENST00000510730.5 D6RBG6 |